Biotechs are in very early stage of bull run. According to HH, SRX will be one of best performing biotechs in upcoming year. Adding more down here . Anticipation of surging earnings and play of Sir Spheres becoming standard of care as inclusion in oncology treatments for tumors to liver is not yet factored into sp.Terrific entry point for those not yet long as Huntley looking for double in short to medium term
